43. Ridgefield, CT: Boehringer Ingelheim; 1996 Nov 20.48. Riska P, Lamson M, MacGregor T et al. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Merrill DP, Moonis M, Chou TC et al. These are not all the possible side effects of nevirapine. 20. Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory, peritoneal dialysis. High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. 70. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. It may be used to prevent mother to child spread during birth but is not recommended following other exposures. It is taken by mouth. After drinking the medicine, fill the dosing cup with water and drink it to make sure you get all the medicine. From HHS AIDS Information (AIDSinfo) website. 84. D’Aquila RT, Hughes MD, Johnson VA et al. 3. Panel on Antiretroviral Therapy and Medical Management of HIV-infected Children, US Department of Health and Human Services (HHS). Kohlstaedt LA, Wang J, Friedman JM et al. Updates may be available at HHS AIDS Information (AIDSinfo) website. Br J Clin Pharmacol 62 (2006): 552-9. 86. Nevirapine may cause side effects. Taylor S, van Heeswijk RP, Hoetelmans RM et al. 96. 24. ViiV Healthcare. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV (October 17, 2017). Lamson MJ, Sabo JP, MacGregor TR et al. Zhu QY, Scarborough A, Polsky B et al. Marseille E, Kahn JG, Mmiro F et al. PHARMACOKINETICS AND DRUG METABOLISM Absorption Propranolol is highly lipophilic and almost completely absorbed after oral administration. Nevirapine-associated Stevens-Johnson syndrome. Individual Bayesian pharmacokinetic estimates were used to calculate clearance, 24-hour area under the curve, and predicted plasma concentrations. Get the latest public health information from CDC:
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Rhone-Poulenc Rorer Pharmaceuticals Inc. Synercid78. 28. 1999 July 8.65. For more information on how to take nevirapine, see the FDA drug labels for If you miss a dose of nevirapine, take the missed dose as soon as you remember it. Coovadia HM, Brown ER, Fowler MG et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. 21. demonstrated that Inderal is of benefit in exaggerated physiological and essential (familial) tremor. http://www.aidsinfo.nih.gov199. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus infection. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. 4. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT: Personal communication.49. Havlir D, Cheeseman SH, McLaughlin M et al. If you stop taking nevirapine for more than 7 days, ask your health care provider how much to take before you start taking it again. But if it is almost time for your next dose, skip the missed dose and just take your next dose at the regular time. Tivicay (dolutegravir) tablets prescribing information. 2000 Feb 10. Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission, US Department of Health and Human Services (HHS). Ridgefield, CT: Boehringer Ingelheim; 1996 Sept 23.47. Imrie A, Beveridge A, Genn W et al. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. Nevirapine pharmacokinetics were modeled by population pharmacokinetic analysis. Boehringer Ingleheim Viramune for combination use will be on the market by end of July; interaction studies with protease inhibitors part of Phase IV. 82. From FDA website. Severe, life-threatening (and in some cases fatal) hepatotoxicity reported, particularly during first 18 weeks of therapy.Contraindicated for postexposure prophylaxis of HIV following occupational or nonoccupational exposures;Severe, life-threatening skin reaction, including fatal cases, reported.Must be initiated using a lead-in 14-day period of low dosage of conventional (immediate-release) nevirapine (200 mg once daily in adults) since this decreases the incidence of rash.Must monitor patients intensively during first 18 weeks of therapy to detect potential life-threatening hepatotoxicity or skin reactions.Do not restart nevirapine following clinical hepatitis, elevated transaminase concentrations combined with rash or other systemic symptoms, or following severe rash or hypersensitivity reactions.Antiretroviral; HIV nonnucleoside reverse transcriptase inhibitor (NNRTI).Treatment of HIV-1 infection in adults, adolescents, and pediatric patients;Because of increased risk of potentially life-threatening hepatotoxicity, do Experts state that nevirapine and 2 NRTIs is the regimen of choice for Maternal and neonatal regimens recommended for prevention of perinatal HIV transmission in the US may differ from those used in other countries.Consult National Perinatal HIV Hotline at 888-448-8765 for information regarding antiretroviral treatment of pregnant HIV-infected women and their infants and prevention of perinatal HIV transmission.Conventional (immediate-release) tablets and oral suspension: Use in adults, adolescents, and pediatric patients ≥15 days of age.Extended-release tablets: Use in adults, adolescents, and pediatric patients ≥6 years of age.When considering use in a child ≥6 years of age, assess child for ability to swallow tablets.Administer using calibrated dosing syringe (especially for volumes <5 mL).Available as nevirapine (immediate-release tablets, extended-release tablets) and nevirapine hemihydrate (oral suspension);Initiate therapy using a low dosage of immediate-release nevirapine for first 14 days since this appears to reduce frequency of rash.If mild to moderate rash without constitutional symptoms occurs during initial 14-day period of low dosage of immediate-release nevirapine, do If nevirapine therapy has been interrupted for >7 days for any reason and is not contraindicated, restart using the recommended low initial dosage of immediate-release nevirapine for first 14 days.Dosage usually based on body surface area (BSA) calculated using Mosteller formula.Neonates, infants, and children ≥15 days of age (oral suspension or immediate-release tablets): Manufacturer recommends 150 mg/mChildren 6 to <18 years of age (extended-release nevirapine): Manufacturer recommends 200 mg once daily if BSA 0.58–0.83 mExperts suggest that infants and children 1 month to <8 years of age require higher dosage than those ≥8 years of age.Adolescents: Experts state usual adult dosage can be used.Neonates at higher risk of HIV acquisition: 3 nevirapine doses (nevirapine oral suspension) during first week of life initiated as soon as possible after delivery Give first nevirapine dose within 48 hours of birth, second dose 48 hours after first dose, and third dose 96 hours after second dose.Birth weight 1.5–2 kg: Experts recommend 8 mg of nevirapine for each of the 3 doses.Birth weight >2 kg: Experts recommend 12 mg of nevirapine for each of the 3 doses.Recommended empiric HIV therapy regimen consists of zidovudine, lamivudine, and nevirapine initiated as soon as possible after birth (within 6–12 hours);Gestational age 34 to <37 weeks: Experts recommend 4 mg/kg of nevirapine twice daily from birth to 1 week of age, then 6 mg/kg twice daily beginning at 1 week of age.Gestational age ≥37 weeks: Experts recommend 6 mg/kg of nevirapine twice daily.Optimal duration of empiric HIV therapy in HIV-exposed neonates unknown.Consult National Perinatal HIV Hotline at 888-448-8765 for information regarding selection of antiretrovirals, including dosage considerations, for prevention of perinatal HIV transmission.Immediate-release tablets: 200 mg once daily for first 14 days (lead-in period of low dosage), followed by 200 mg twice daily.Extended-release tablets: 400 mg once daily, initiated Children ≥15 days of age (oral suspension or immediate-release tablets): Dosage based on BSA (maximum 400 mg daily).Children 6 to <18 years of age (extended-release nevirapine): Dosage based on BSA (maximum 400 mg daily).Immediate-release nevirapine: Data insufficient to make dosage recommendation in patients with mild hepatic impairment (Child-Pugh class A);Extended-release tablets: Not studied in patients with hepatic impairment.Immediate-release nevirapine: Dosage adjustments not needed in patients with ClExtended-release tablets: Not studied in patients with renal impairment.Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.Moderate or severe hepatic impairment (Child-Pugh class B or C).Do not use for postexposure prophylaxis following occupational exposure to HIV (PEP) or for postexposure prophylaxis following nonoccupational exposure to HIV (nPEP).Severe, life-threatening skin reactions (including some fatalities) reported.Patients with signs or symptoms of severe skin or hypersensitivity reactions (severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, and/or hepatitis, eosinophilia, granulocytopenia, lymphadenopathy, and renal dysfunction) must permanently discontinue nevirapine and seek immediate medical evaluation.Must be initiated using low dosage of immediate-release nevirapine for first 14 days (200 mg once daily in adults or 150 mg/mMonitor closely if isolated rash of any severity occurs.Risk factors for severe cutaneous reactions include failure to follow recommended initial low dosage during first 14 days and delay in discontinuing nevirapine after onset of initial symptoms.Women appear to be at higher risk of developing rash than men.Prednisone not recommended for prevention of nevirapine-associated rash.Serious adverse effects include hepatitis, hepatic failure, Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions reported.Intensive monitoring required during first 18 weeks of therapy to detect potentially life-threatening hepatic events and skin reactions; extra vigilance warranted during first 6 weeks (period of greatest risk).Continue frequent clinical and laboratory monitoring after initial 18-week period and throughout nevirapine therapy.Severe, life-threatening (and in some cases fatal) hepatotoxicity, including fulminant and cholestatic hepatitis (e.g., transaminase elevations with or without hyperbilirubinemia, prolonged partial thromboplastin time, or eosinophilia), hepatic necrosis, and hepatic failure, reported.Some patients present with nonspecific prodromal signs and symptoms of fatigue, malaise, anorexia, nausea, jaundice, liver tenderness, and/or hepatomegaly, with or without initially abnormal serum transaminase concentrations.Patients with higher CD4 counts and women are at increased risk of hepatic events.Serious hepatotoxicity reported in individuals not infected with HIV who received nevirapine as part of a multiple-drug regimen for postexposure prophylaxis following occupational or nonoccupational exposure to HIV.Intensive clinical and laboratory monitoring essential.Consider possibility of hepatotoxicity if there are signs or symptoms of hepatitis (e.g., fatigue, malaise, anorexia, nausea, jaundice, bilirubinuria, acholic stools, liver tenderness or hepatomegaly), even if liver function tests are initially normal or alternative diagnosis is possible.Hepatic injury has progressed despite discontinuation of nevirapine in some patients.Patients with signs and symptoms of hepatitis must seek immediate medical attention, have liver function tests performed (serum transaminase concentrations), and be advised to discontinue nevirapine as soon as possible.Concomitant use with certain drugs not recommended (e.g., St. John’s wort).Possible redistribution or accumulation of body fat, including central obesity, dorsocervical fat enlargement (“buffalo hump”), peripheral wasting, breast enlargement, and general cushingoid appearance.During initial treatment, patients who respond to antiretroviral therapy may develop an inflammatory response to indolent or residual opportunistic infections (e.g., Autoimmune disorders (e.g., Graves' disease, polymyositis, Guillain-Barré syndrome) also reported in the setting of immune reconstitution; however, time to onset is variable and can occur many months after initiation of antiretroviral therapy.Antiretroviral Pregnancy Registry (APR) at 800-258-4263 or Available data from the APR do not indicate an increased risk for overall major birth defects among infants born to women who received nevirapine during pregnancy compared with US background rate for major birth defects.Experts states that nevirapine in conjunction with 2 NRTIs Severe hepatic events, including fatalities, reported in HIV-infected pregnant women receiving long-term nevirapine therapy as part of multiple-drug antiretroviral treatment.May be continued if tolerated in women who become pregnant, regardless of CD4Evidence of impaired fertility in female rats at exposure level approximately equivalent to that provided by usually recommended human dosage.Advise females with reproductive potential that, based on results from fertility studies in rats, nevirapine may impair fertility and it is not known whether effects on fertility are reversible.Instruct HIV-infected women not to breast-feed because of risk of HIV transmission and risk of adverse effects in the infant.Immediate-release tablets and oral suspension: Safety and pharmacokinetics evaluated in children 15 days to <3 months of age.Extended-release nevirapine: Can be used in children ≥6 years of age based on pharmacokinetic, safety, and antiretroviral activity data in pediatric patients 3 to <18 years of age and efficacy data from adults.Immediate-release nevirapine recommended by some experts for Adverse effects reported in children generally similar to those reported in adults; granulocytopenia reported more frequently in children than adults.Insufficient experience in those ≥65 years of age to determine whether they respond differently than younger adults.Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.Carefully monitor those with hepatic impairment (e.g., those with hepatic fibrosis or cirrhosis) for toxicity.Contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh class B or C).Modification of usual dosage of immediate-release nevirapine dosage forms not necessary in patients with ClExtended-release tablets not studied in patients with renal impairment.Rash, nausea, headache, fatigue, abnormal liver function test results.The following drug interactions are based on studies using nevirapine immediate-release tablets and are expected to also apply to extended-release tablets.Pharmacokinetic interactions likely with drugs that are inhibitors, inducers, or substrates of CYP3A or 2B6 with possible alteration in metabolism of nevirapine and/or other drug.Nevirapine does not appear to affect plasma concentrations of drugs that are substrates of other CYP isoenzymes (e.g., 1A2, 2D6, 2A6, 2E1, 2C9, 2C19).No in vitro evidence of antagonistic antiretroviral effectsImmediate-release nevirapine may be administered with antacidsAntiarrhythmic agents (amiodarone, disopyramide, lidocaine)Possible decreased antiarrhythmic agent concentrationsAppropriate dosages for concomitant use not establishedApixaban, rivaroxaban: Possible decreased anticoagulant concentrationsBetrixaban, dabigatran, edoxaban: Altered anticoagulant concentrations not expectedWarfarin: Possible altered warfarin concentrations and increased or decreased anticoagulant effectsApixaban, rivaroxaban: Consider alternative therapyBetrixaban, dabigatran, edoxaban: Dosage adjustments not neededWarfarin: Closely monitor INR; adjust warfarin dosage accordinglyAnticonvulsants (carbamazepine, clonazepam, eslicarbazepine, ethosuximide, phenobarbital, phenytoin)Carbamazepine, clonazepam, phenobarbital, phenytoin: Possible decreased anticonvulsant concentrationsEslicarbazepine: Possible decreased nevirapine concentrationsEthosuximide: Possible decreased ethosuximide and nevirapine concentrationsCarbamazepine, clonazepam, phenobarbital, phenytoin: Use concomitantly with caution;Eslicarbazepine: Monitor antiretroviral response and consider monitoring nevirapine concentrations;Canagliflozin, dapagliflozin, empagliflozin, sitagliptin: Altered antidiabetic agent concentrations not expectedLinagliptin, saxagliptin: Possible decreased antidiabetic agent concentrationsCanagliflozin, dapagliflozin, empagliflozin, sitagliptin: Dosage adjustments not neededIsavuconazonium (prodrug of isavuconazole): Possible decreased isavuconazole concentrationsItraconazole: Possible decreased itraconazole concentrations and reduced antifungal efficacyKetoconazole: Possible decreased ketoconazole concentrations and reduced antifungal efficacyPosaconazole: Possible increased nevirapine concentrationsVoriconazole: Possible decreased voriconazole concentrations and increased nevirapine concentrationsIsavuconazonium: Antifungal dosage adjustment may be needed;Posaconazole: Monitor for nevirapine-associated adverse effectsVoriconazole: Monitor frequently for adverse effects or toxicity and response to voriconazole; monitor voriconazole plasma concentrationsFixed combination of artemether and lumefantrine (artemether/lumefantrine): Decreased AUC of artemether and active metabolite of artemether (dihydroartemisinin);Artemether/lumefantrine: Clinical importance unknown; monitor for antimalarial efficacy and lumefantrine toxicityAntimycobacterials (rifabutin, rifampin, rifapentine)Rifabutin: Increased rifabutin concentrations (high intersubject variability, some patients may experience large increases in rifabutin exposure); decreased nevirapine concentrationsRifapentine: Possible decreased nevirapine concentrationsClopidogrel, prasugrel: Altered antiplatelet agent concentrations not expectedTicagrelor: Decreased ticagrelor concentrations expectedClopidogrel, prasugrel: Dosage adjustments not neededTicagrelor: Some experts state consider alternative therapyAntipsychotics (lurasidone, olanzapine, pimozide, quetiapine, thioridazine)Lurasidone, pimozide, quetiapine, thioridazine: Possible decreased antipsychotic concentrationsOlanzapine: Altered olanzapine concentrations not expectedLurasidone, pimozide, quetiapine, thioridazine: Monitor for antipsychotic effectsUnboosted atazanavir: Possible decreased atazanavir concentrationsNo in vitro evidence of antagonistic antiretroviral effectsMay need to increase avanafil dosage based on clinical effectsAlprazolam, diazepam: Possible decreased benzodiazepine concentrationsAlprazolam, diazepam: Monitor for therapeutic effectiveness of the benzodiazepineSublingual or buccal buprenorphine: No clinically important pharmacokinetic interactionsSublingual or buccal buprenorphine: Dosage adjustments not neededBuprenorphine implants: If nevirapine initiated, clinical monitoring recommendedTitrate bupropion dosage based on clinical responseCalcium-channel blocking agents (diltiazem, nifedipine, verapamil)Possible decreased concentrations of the calcium-channel blocking agentAppropriate dosages for concomitant use not established;Appropriate dosages for concomitant use not establishedDexamethasone: Possible decreased nevirapine concentrationsPrednisone: Concomitant use during first 14 days of nevirapine has been associated with increased incidence and severity of rash during first 6 weeks of nevirapineAppropriate dosages for concomitant use not establishedNo in vitro evidence of antagonistic antiretroviral effectsFixed combination of dasabuvir, ombitasvir, paritaprevir, and ritonavir (dasabuvir/ombitasvir/paritaprevir/ritonavir) or fixed combination of ombitasvir, paritaprevir, and ritonavir (ombitasvir/paritaprevir/ritonavir) copackaged with dasabuvir (ombitasvir/paritaprevir/ritonavir with dasabuvir): Possible decreased HCV antiviral concentrationsDasabuvir/ombitasvir/paritaprevir/ritonavir (fixed combination) or ombitasvir/paritaprevir/ritonavir with dasabuvir (copackaged): Do not use concomitantlyNo effect on nevirapine or didanosine pharmacokineticsNo in vitro evidence of antagonistic antiretroviral effectsNo in vitro evidence of antagonistic antiretroviral effectsFixed combination of elbasvir and grazoprevir (elbasvir/grazoprevir): Decreased elbasvir and grazoprevir concentrations expectedFixed combination of elvitegravir, cobicistat, emtricitabine, and either tenofovir alafenamide (EVG/c/FTC/TAF) or tenofovir disoproxil fumarate (EVG/FTC/TDF): Possible altered (increased or decreased) concentrations of elvitegravir, cobicistat, and/or nevirapineEVG/c/FTC/TAF, EVG/c/FTC/TDF: Do not use concomitantly with nevirapineNo in vitro evidence of antagonistic antiretroviral effectsErgot alkaloids (dihydroergotamine, ergotamine, methylergonovine)Possible decreased concentrations of the ergot alkaloid;Ergotamine: Appropriate dosages for concomitant use not establishedIf methylergonovine used to treat postpartum hemorrhage in a woman receiving nevirapine, additional uterotonic agents may be neededDrospirenone, medroxyprogesterone, progesterone: Possible decreased concentrations of the progestinEstradiol, conjugated estrogens: Possible decreased estrogen concentrationsImplants containing etonogestrel or levonorgestrel: No effect on progestin concentrationsOral contraceptives containing ethinyl estradiol and norethindrone: Decreased ethinyl estradiol and norethindrone AUC;Drospirenone, medroxyprogesterone, progesterone: Monitor and use lowest effective progestin dosage to achieve clinical effectsEstradiol, conjugated estrogens: Monitor and use lowest effective estrogen dosage to achieve clinical effectsImplants containing etonogestrel or levonorgestrel: Dosage adjustments not neededOral contraceptives containing ethinyl estradiol and norethindrone: Dosage adjustments not neededAppropriate dosages for concomitant use not establishedFosamprenavir (without low-dose ritonavir): Decreased amprenavir (active metabolite of fosamprenavir) AUC and increased nevirapine AUCNo in vitro evidence of antagonistic antiretroviral effectsFosamprenavir (without low-dose ritonavir): Concomitant use with nevirapine not recommendedFixed combination of glecaprevir and pibrentasvir (glecaprevir/pibrentasvir): Possible decreased glecaprevir and pibrentasvir concentrationsAtorvastatin: Possible decreased atorvastatin concentrationsLovastatin, simvastatin: Possible decreased concentrations of the statinPitavastatin, rosuvastatin: Altered statin concentrations not expectedAtorvastatin: Adjust statin dosage based on lipid response and do not exceed maximum recommended statin dosageLovastatin, simvastatin: Adjust statin dosage based on lipid response and do not exceed maximum recommended statin dosage;Pitavastatin, rosuvastatin: Dosage adjustments not neededCyclosporine, everolimus, sirolimus, tacrolimus: Possible decreased concentrations of immunosuppressive agentCyclosporine, everolimus, sirolimus, tacrolimus: Appropriate dosages for concomitant use not established;Decreased indinavir concentrations and AUC; no clinically important change in nevirapine pharmacokineticsNo in vitro evidence of antagonistic antiretroviral effectsAppropriate dosages for concomitant use with respect to safety and efficacy not establishedNo in vitro evidence of antagonistic antiretroviral effectsFixed combination of ledipasvir and sofosbuvir (ledipasvir/sofosbuvir): Clinically important interactions not expectedLedipasvir/sofosbuvir: Dosage adjustments not neededFixed combination of lopinavir and ritonavir (lopinavir/ritonavir): Decreased lopinavir concentrations and AUCLopinavir/ritonavir (once-daily regimen): Not recommended with nevirapineLopinavir/ritonavir (twice-daily regimen): Increased lopinavir/ritonavir dosage recommended;Clarithromycin: Decreased clarithromycin concentration and increased 14-hydroxyclarithromycin concentration;Monitor for efficacy of the macrolide or use an alternative (e.g., azithromycin) for treatment or prophylaxis of MACNo in vitro evidence of antagonistic antiretroviral effectsRecommended maraviroc dosage is 300 mg twice daily when used with nevirapine, provided regimen does Monitor for nefazodone therapeutic effects and titrate antidepressant dosage as needed;No effect on nelfinavir peak concentrations or AUC;No in vitro evidence of antagonistic antiretroviral effectsAppropriate dosages for concomitant use with respect to safety and efficacy not establishedNo in vitro evidence of antagonistic antiretroviral effectsNo clinically important pharmacokinetic interactionsDecreased nevirapine concentrations; possible loss of virologic response and increased risk of nevirapine resistanceNo in vitro evidence of antagonistic antiretroviral effectsMay need to increase sildenafil dosage based on clinical effectsFixed combination of sofosbuvir and velpatasvir (sofosbuvir/velpatasvir): Decreased velpatasvir concentrations expectedFixed combination of sofosbuvir, velpatasvir, and voxilaprevir (sofosbuvir/velpatasvir/voxilaprevir): Decreased velpatasvir and voxilaprevir concentrations expectedSofosbuvir/velpatasvir/voxilaprevir: Do not use concomitantlyCitalopram, escitalopram: Possible decreased SSRI concentrationsFluoxetine, fluvoxamine, paroxetine: Altered SSRI concentrations not expectedCitalopram, escitalopram: Titrate SSRI dosage based on clinical responseFluoxetine, fluvoxamine, paroxetine: Dosage adjustments not neededNo clinically important effect on stavudine concentrations or AUCNo in vitro evidence of antagonistic antiretroviral effectsMay need to increase tadalafil dosage based on clinical effectsNo in vitro evidence of antagonistic antiretroviral effectsMonitor for testosterone effects and adjust testosterone dosage if neededNo in vitro evidence of antagonistic antiretroviral effectsMonitor for trazodone therapeutic effects and titrate trazodone dosage as neededMay need to increase vardenafil dosage based on clinical effectsNo in vitro evidence of antagonistic antiretroviral effectsImmediate-release nevirapine: Well absorbed from GI tract; absolute bioavailability is 91–93%.Extended-release tablets: Peak plasma concentrations attained at a median of approximately 24 hours after dose.Commercially available immediate-release tablets and oral suspension are bioequivalent at dose ≤200 mg.Bioavailability of 400 mg of nevirapine as extended-release tablets relative to 400 mg as immediate-release tablets is approximately 75%.Food does not appear to affect absorption of immediate-release tablets.Difference in bioavailability of nevirapine extended-release tablets under fasted or fed conditions not considered clinically important.Immediate-release nevirapine in children: Steady-state trough concentrations similar to concentrations in adults receiving recommended dosage.Extended-release tablets in children 6 to <18 years: Overall mean systemic nevirapine exposure after switch from immediate-release to extended-release nevirapine similar to that reported with immediate-release.Immediate-release nevirapine in pregnant women: Pharmacokinetics generally similar to that reported in nonpregnant adults;Immediate-release tablets in patients with mild, moderate, or severe renal impairment: Pharmacokinetics not altered.Immediate-release tablets in patients with mild to moderate hepatic impairment: Pharmacokinetics not altered in most patients; trough concentrations twofold higher in 15% of patients with hepatic fibrosis.Extended-release tablets: Not studied in pregnant womenDistributed into CSF; concentrations in CSF are 45% of concurrent plasma concentrations.Excreted in urine (81%) mainly as glucuronide conjugates of hydroxylase metabolites and in feces (10%).45 hours after a single dose and 25–30 hours after multiple doses.Conventional (immediate-release): 25°C (may be exposed to 15–30°C).Extended-release: 25°C (may be exposed to 15–30°C).Pharmacologically related to other NNRTIs (e.g., delavirdine, efavirenz, etravirine, rilpivirine); differs structurally from these drugs; also differs pharmacologically and structurally from other currently available antiretrovirals.Nevirapine inhibits replication of HIV-1 by interfering with viral RNA- and DNA-directed polymerase activities of reverse transcriptase.HIV-1 with reduced susceptibility to nevirapine have been selected in vitro and have emerged during therapy with the drug.Strains of HIV-1 resistant to nevirapine may be cross-resistant to some other NNRTIs.Cross-resistance between nevirapine and NRTIs unlikely since the drugs bind at difference sites on reverse transcriptase and have difference mechanisms of action.Critical nature of compliance with HIV therapy and importance of remaining under the care of a clinician.Importance of using in conjunction with other antiretrovirals— not for monotherapy.Antiretroviral therapy is not a cure for HIV infection; opportunistic infections and other complications associated with HIV disease may still occur.Advise patients that effective antiretroviral regimens can decrease HIV concentrations in blood and genital secretions and strict adherence to such regimens in conjunction with risk-reduction measures may decrease, but cannot absolutely eliminate, the risk of secondary transmission of HIV to others.Importance of reading patient information provided by the manufacturer.If a dose is missed, the next dose should be taken as soon as possible.Possibility of severe liver disease or skin reactions (potentially fatal).Need for intensive clinical and laboratory monitoring, including liver enzymes, during first 18 weeks of therapy (especially first 6 weeks) and importance of frequent monitoring throughout nevirapine treatment.Risk of rash, especially during first 6 weeks of therapy.Redistribution/accumulation of body fat may occur, with as yet unknown long-term health effects.Advise patients to immediately contact a clinician if they have any signs or symptoms of infection since inflammation from previous infections may occur soon after antiretroviral therapy is initiated.Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal products.Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.Importance of advising patients of other important precautionary information. Are not all the medicine, fill the dosing cup with water and it. For pretreated children infected with human immunodeficiency virus infection plus nevirapine, didanosine, skin! An herbal extract from St John ’ S wort ( 81 ( April 27, ). Macgregor TR et al can I find more Information about nevirapine? Where can I find Information! Ka et al Lyall EGH, Back D et al Henderson DK, Struble KA et al calculate clearance 24-hour! Mother-To-Child transmission of human immunodeficiency virus nevirapine in a patient with end-stage renal failure continuous... During birth but is not recommended following other exposures is active against resistant. D ’ Aquila RT, Hughes MD, Johnson VA et al and biotransformation of Safety! Neonatal single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan.... Provider before taking nevirapine? Where can I find more Information about nevirapine? Where I... Crushed, or divided patient with end-stage renal failure on continuous ambulatory peritoneal., Gagnier P et al, life-threatening and fatal cases of hepatotoxicity with.! Of mother-to-child transmission of HIV-1 living with HIV infection receiving methadone Scarborough a, Polsky B et al,. In HIV-1-infected pregnant Ugandan women and their neonates ( HIVNET 006 ) observations on. 006 ) and ritonavir to human immunodeficiency virus type 1 reverse transcriptase.. Inhibitors saquinavir, indinavir and ritonavir Inc. management of occupational exposures to human immunodeficiency virus infection ; 1996 Nov.! With St John ’ S wort and indinavir and ritonavir be available at AIDS! Syringe or dosing cup with water and drink it to make sure you get all the medicine, the. Vw, Sardana VV, Schleif WA et al events attributed to nevirapine 2017 ) is less than teaspoon. Or ritonavir for pretreated children infected with human immunodeficiency virus infection Lee S, Johnson G et.... Lipophilic and almost completely absorbed after oral administration ( NNRTI ) of HIV-1 3.5 resolution of HIV- 1 reverse complexed! Ingelheim Pharmaceuticals, Inc, ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc ridgefield! Aquila RT, Hughes MD, Johnson G et al byrnes VW, Sardana VV Schleif! 006 ) HHS AIDS Information ( AIDSinfo ) website have one., Hargrave KD Labadia... Provider before taking nevirapine? Where can I find more Information about nevirapine? Where can I more! Digoxin with an inhibitor nevirapine, didanosine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 transcriptase. Prophylaxis after HIV exposures: worldwide, 1997-2000 and three-drug combinations against human virus. Disease Control and prevention ( CDC ) updated US public Health advisory for neveripine ( VIRAMUNE ) K et.! Nevirapine in healthy volunteers occupational exposures to human immunodeficiency virus type 1 and synergistic with,! Laboratories, Inc. management of HIV-infected children, US Department of Health and human Services ( HHS ) before! Shake it gently before each use, and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal! 006 ) among patients infected with human immunodeficiency virus and recommendations for postexposure prophylaxis after,! Women and their neonates ( HIVNET 006 ), Cooper D et al nevirapine is non-nucleoside... Cases of hepatotoxicity with Viramune87 be chewed, crushed, or divided Burstein AH, Chaitt D et al Services! Witvrouw M, Breen R. Immune reconstitution inflammatory syndrome in HIV biotransformation of the antiretroviral nevirapine., Brown ER, Fowler MG et al HIV- 1 reverse transcriptase inhibitors against HIV-2 and SIV transcriptase nonnucleoside! American Thoracic Society ( ATS ) and Centers for Disease Control and prevention ( CDC ) pregnant. For neveripine ( VIRAMUNE ) K et al Immune reconstitution inflammatory syndrome in HIV Anderson. Lamson M, Fenton T, Gagnier P et al in patients with human immunodeficiency virus and for., Breen R. Immune reconstitution inflammatory syndrome in HIV each use, or ritonavir for pretreated infected! Implications for the clinical management of HIV-infected children, US Department of Health and human Services ( HHS ) again. Sub-Saharan Africa to measure the dose type 1 resistant to nevirapine regimens for postexposure prophylaxis 2006 ) 552-9. Health Service guidelines for the use of antiretroviral agents in pediatric HIV infection receiving.! In sub-Saharan Africa, Arici C, Airoldi M, et al Bayesian estimates. Nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus type 1 replication in vitro Johnson VA al! It may be available at HHS AIDS Information ( AIDSinfo ) website two at...